10-KPeriod: FY2013

ABBOTT LABORATORIES Annual Report, Year Ended Dec 31, 2013

Filed February 21, 2014For Securities:ABT

Summary

Abbott Laboratories filed its 2013 10-K on February 20, 2014, reporting on its business and financial performance for the fiscal year ended December 31, 2013. A significant event for the company was the January 1, 2013 separation of its research-based pharmaceuticals business into an independent entity, AbbVie Inc. This separation resulted in the proprietary pharmaceutical products segment being presented as discontinued operations, allowing Abbott to focus on its diversified healthcare products. The company's remaining segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Financially, Abbott demonstrated resilience, with net sales showing an increase. The company highlighted growth in its Nutritional and Diagnostic segments, driven by demographic trends and new product introductions. However, the Established Pharmaceutical Products segment faced macroeconomic and market pressures, particularly in emerging markets, while the Vascular Products segment experienced pricing pressure and a decline in U.S. market due to competition and market conditions. The company also addressed its ongoing commitment to research and development, investing significantly to drive future innovation across its business segments.

Financial Highlights

55 data points
Beta

Revenue

$19.66B

53.2% Gross Margin

Net Income

$2.58B

13.1% Net Margin

EPS (Diluted)

$1.62

Total Assets

$42.94B

Cash & Equivalents

$3.48B

Free Cash Flow

$2.18B

Financial Statements
Beta
Revenue$19.66B
Cost of Revenue$9.19B
Gross Profit$10.46B
SG&A Expenses$6.37B
Operating Expenses$17.52B
Operating Income$2.13B
Interest Expense$145.00M
Net Income$2.58B
EPS (Basic)$1.64
EPS (Diluted)$1.62
Shares Outstanding (Basic)1.56B
Shares Outstanding (Diluted)1.57B

Key Highlights

  • 1Abbott completed the separation of its research-based pharmaceutical business (AbbVie Inc.) on January 1, 2013, refocusing on diversified healthcare products across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.
  • 2Net sales increased to $21.8 billion in 2013 from $21.5 billion in 2012, reflecting growth driven by the Nutritional and Diagnostic segments.
  • 3The Nutritional Products segment saw sales growth of 4.3% (excluding foreign exchange), benefiting from demographic trends and new product introductions, although a product recall in China impacted performance in the latter half of the year.
  • 4The Diagnostic Products segment reported a 5.9% increase in sales (excluding foreign exchange), driven by unit growth across geographical regions and continued execution of integrated solutions for healthcare customers.
  • 5The Established Pharmaceutical Products segment faced challenges with a 2.9% decrease in sales (excluding foreign exchange), largely due to market pressures in emerging markets and austerity measures in developed markets.
  • 6The Vascular Products segment saw a 1.9% decrease in sales (excluding foreign exchange), impacted by pricing pressure on drug-eluting stents and a decline in U.S. market procedures.
  • 7Abbott spent approximately $1.5 billion on research and development in 2013, underscoring its commitment to innovation across its core segments.

Frequently Asked Questions

The most significant event was the completion of the separation of Abbott's research-based proprietary pharmaceuticals business into a new, independent company called AbbVie Inc. This separation occurred on January 1, 2013, and resulted in the proprietary pharmaceutical business being presented as discontinued operations in Abbott's financial statements for 2013.

The separation meant that Abbott's reported net sales for 2013 of $21.8 billion represent its diversified healthcare products, excluding the former pharmaceutical business. Earnings from continuing operations were $2.4 billion, while net earnings were $2.6 billion, reflecting the exclusion of AbbVie's results from continuing operations. The discontinued operations segment reported significant earnings as well.

The Nutritional Products segment and the Diagnostic Products segment showed strong performance with sales growth. The Established Pharmaceutical Products segment and the Vascular Products segment faced challenges, with declining sales primarily due to market pressures, pricing competition, and macroeconomic factors.

Abbott's strategy involves focusing on key initiatives within each segment: expanding its product portfolio and emerging markets in Nutritional Products; developing next-generation platforms in Diagnostics; expanding its presence in emerging markets for Established Pharmaceuticals; and continuing to market its Xience and endovascular franchises, along with developing new technologies like Absorb and MitraClip in Vascular Products. The company also plans to continue investing in R&D.